Echocardiographic Characterization of Myocardial Stiffness in Healthy Volunteers, Cardiac Amyloidosis, and Hypertrophic Cardiomyopathy: A Case-Control Study Using Multimodality Imaging

Background: Noninvasive tools to measure myocardial stiffness are limited. Intrinsic cardiac elastography in echocardiography relates to myocardial stiffness by measuring the propagation of the myocardial stretch generated by atrial contraction. The aims of the present study were (1) to evaluate myocardial stiffness using intrinsic cardiac elastography in healthy volunteers versus those with myocardial diseases (ie, cardiac amyloidosis [CA] and hypertrophic cardiomyopathy) and (2) to identify key factors that affect myocardial stiffness. Methods: In this prospective study, myocardial stiffness was estimated in 54 participants, including 10 hypertrophic cardiomyopathy, 28 CA, and 16 healthy volunteers. Myocardial stiffness was assessed as intrinsic velocity propagation of myocardial stretch (iVP, m/s) measured by high frame rate echocardiography (ie, above 250 frames per second). Extracellular volume was quantified by cardiac magnetic resonance in 22 participants. Amyloid burden was quantified by cardiac amyloid activity in $^{99m}$Tc-labeled pyrophosphate single-photon emission computed tomography in 10 participants. Results: Myocardial stiffness was significantly higher in the CA cohort (median iVP, 2.6 m/s; interquartile range, 1.7-3.9 m/s) than in the hypertrophic cardiomyopathy cohort (median iVP, 1.4 m/s; interquartile range, 1.0-1.8 m/s; P=0.011). In patients with CA or hypertrophic cardiomyopathy, iVP was correlated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) (ρ=0.498, P=0.003), extracellular volume (ρ=0.646, P=0.004), and cardiac amyloid activity (ρ=0.891, P<0.001). In multivariate linear regression analysis, extracellular volume was independently associated with myocardial stiffness even after accounting for indexed left ventricular mass, global longitudinal strain, and E/e'. In healthy volunteers, normal myocardial stiffness was defined by the upper limit of normal of iVP at 1.7 m/s. Patients with CA and normal myocardial stiffness (iVP <1.7 m/s) were characterized by a low risk profile including lower NT-proBNP (P=0.034), lower troponin T (P=0.041), lower National Amyloidosis Center stage (P=0.031), smaller interstitial expansion (P=0.014), and smaller amyloid burden (P=0.056). Conclusions: Intrinsic cardiac elastography is a reliable noninvasive tool to measure myocardial stiffness. In this pilot study, it is related to imaging markers of interstitial expansion and amyloid burden.

Authors

Publication Details

Journal
Universität Zürich, ZORA
Published
2025-03-01
DOI
https://doi.org/10.5167/uzh-283382
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Echocardiographic Characterization of Myocardial Stiffness in Healthy Volunteers, Cardiac Amyloidosis, and Hypertrophic Cardiomyopathy: A Case-Control Study Using Multimodality Imaging

Pat Rafter, S. Vijayakumar, Dominik Carlo Benz, Ali Sadeghi et al.
Universität Zürich, ZORA
Amyloidosis: Diagnosis, Treatment, Outcomes
article

Echocardiographic Characterization of Myocardial Stiffness in Healthy Volunteers, Cardiac Amyloidosis, and Hypertrophic Cardiomyopathy: A Case-Control Study Using Multimodality Imaging

Pat Rafter, S. Vijayakumar, Dominik Carlo Benz, Ali Sadeghi, Alexandra Taylor, Rodney H Falk, Sarah Cuddy, Olivier Florian Clerc, Carolyn Ho, Jocelyn Canseco Neri, Sharmila Dorbala
article en

Abstract

Background: Noninvasive tools to measure myocardial stiffness are limited. Intrinsic cardiac elastography in echocardiography relates to myocardial stiffness by measuring the propagation of the myocardial stretch generated by atrial contraction. The aims of the present study were (1) to evaluate myocardial stiffness using intrinsic cardiac elastography in healthy volunteers versus those with myocardial diseases (ie, cardiac amyloidosis [CA] and hypertrophic cardiomyopathy) and (2) to identify key factors that affect myocardial stiffness. Methods: In this prospective study, myocardial stiffness was estimated in 54 participants, including 10 hypertrophic cardiomyopathy, 28 CA, and 16 healthy volunteers. Myocardial stiffness was assessed as intrinsic velocity propagation of myocardial stretch (iVP, m/s) measured by high frame rate echocardiography (ie, above 250 frames per second). Extracellular volume was quantified by cardiac magnetic resonance in 22 participants. Amyloid burden was quantified by cardiac amyloid activity in $^{99m}$Tc-labeled pyrophosphate single-photon emission computed tomography in 10 participants. Results: Myocardial stiffness was significantly higher in the CA cohort (median iVP, 2.6 m/s; interquartile range, 1.7-3.9 m/s) than in the hypertrophic cardiomyopathy cohort (median iVP, 1.4 m/s; interquartile range, 1.0-1.8 m/s; P=0.011). In patients with CA or hypertrophic cardiomyopathy, iVP was correlated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) (ρ=0.498, P=0.003), extracellular volume (ρ=0.646, P=0.004), and cardiac amyloid activity (ρ=0.891, P<0.001). In multivariate linear regression analysis, extracellular volume was independently associated with myocardial stiffness even after accounting for indexed left ventricular mass, global longitudinal strain, and E/e'. In healthy volunteers, normal myocardial stiffness was defined by the upper limit of normal of iVP at 1.7 m/s. Patients with CA and normal myocardial stiffness (iVP <1.7 m/s) were characterized by a low risk profile including lower NT-proBNP (P=0.034), lower troponin T (P=0.041), lower National Amyloidosis Center stage (P=0.031), smaller interstitial expansion (P=0.014), and smaller amyloid burden (P=0.056). Conclusions: Intrinsic cardiac elastography is a reliable noninvasive tool to measure myocardial stiffness. In this pilot study, it is related to imaging markers of interstitial expansion and amyloid burden.

Universität Zürich, ZORA
Good health and well-being
Openalex Percentile: Top 34%
Amyloidosis: Diagnosis, Treatment, Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.